Business
Revenue expected to triple by 2027: Focus on growth markets for medical cannabis and industrial hemp underscores positive outlook for SYNBIOTIC
Revenue expected to triple by 2027: Focus on growth markets for medical cannabis and industrial hemp underscores positive outlook for SYNBIOTIC
About this update from Synbiotic Se
EQS-News: SYNBIOTIC SE / Key word(s): Strategic Company Decision/Development of SalesRevenue expected to triple by 2027: Focus on growth markets for medical cannabis and industrial hemp underscores positive outlook for SYNBIOTIC 29.07.2025 / 12:54 CET/CESTThe issuer is solely responsible for the content of this announcement. Revenue expected to triple by 2027: Focus on growth markets for medical cannabis and industrial hemp underscores positive outlook for SYNBIOTICThe European company group for medical cannabis and industrial hemp SYNBIOTIC SE (ISIN | WKN A3E5A5) will focus its strategic expansion even more on the fastest-growing markets for medical cannabis and industrial hemp in the future.Two fast-growing billion-euro markets create investment opportunitiesAt the heart of SYNBIOTIC's strategy is a dual market approach that captures long-term value in both the medical cannabis and industrial hemp markets. Daniel Kruse, CEO of the company group, sees this as a clear focus and sustainable positioning for the future: "With our strategy, we enable our investors to benefit from both the positive developments in the medical cannabis market and the strong upturn in the industrial hemp sector. This is a unique opportunity for investors."Global market for medical cannabis growing by 55 per cent annuallyAccording to forecasts, the global market for medical cannabis will grow at an annual rate of 55 percent from EUR 4.5 billion in 2024 to around EUR 62 billion in 2030. Growth drivers include ongoing legalisation, increasing social acceptance and the integration of cannabis into standard medical care. SYNBIOTIC's extensive range of medical cannabis products includes cannabis flowers, alternative dosage forms (e.g. cannabinoid pastilles), high-purity extracts and dronabinol.The subsidiary WEECO Pharma GmbH has global import licences (e.g. Canada, South America and Thailand) and, together with GOC NEXUS as a cooperation partner, uses cold plasma technology to guarantee GMP (Good Manufacturing Practice) quality standards for cannabis flowers.Excellent positioning with regard to German draft legislationThe current draft bill to amend the Medical Cannabis Act (MedCanG) aims to restrict the prescription of cannabis to personal doctor-patient contact and exclude mail order sales. The German Cannabis Industry Association (BvCW), SYNBIOTIC as a member company of the BvCW a...